 |
156 Diseases |  |
15 Trials |
|
15 Trials |  |
235 News |  |
| «1234» |
- |||| ondansetron / Generic mfg., cisplatin / Generic mfg.
Trial completion: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) (clinicaltrials.gov) - Apr 23, 2017
P4, N=477, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed
- | aprepitant oral / Generic mfg.
Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Apr 19, 2017
P2, N=4, Terminated, Sponsor: The Hospital for Sick Children
No longer recruiting --> Completed Trial primary completion date: Sep 2018 --> Sep 2016
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) (clinicaltrials.gov) - Apr 17, 2017
P3, N=584, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2018 --> Sep 2016 No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) (clinicaltrials.gov) - Apr 17, 2017
P3, N=468, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- | olanzapine / Generic mfg.
Enrollment open: Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (clinicaltrials.gov) - Apr 12, 2017
P3, N=120, Recruiting, Sponsor: CCTU
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai
Review, Journal: NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. (Pubmed Central) - Apr 12, 2017
Not yet recruiting --> Recruiting Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.
- | olanzapine / Generic mfg.
New P3 trial: Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (clinicaltrials.gov) - Mar 24, 2017
P3, N=120, Recruiting, Sponsor: CCTU
- | cyclophosphamide / Generic mfg.
Phase classification: NRR: Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer (clinicaltrials.gov) - Mar 1, 2017
P1, N=19, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK. Phase classification: P=N/A --> P1
- | aprepitant oral / Generic mfg.
Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Feb 23, 2017
P2, N=4, Terminated, Sponsor: The Hospital for Sick Children
Phase classification: P=N/A --> P1 Trial primary completion date: Sep 2016 --> Sep 2018
- | aprepitant oral / Generic mfg., cyclophosphamide oral / Generic mfg., Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
Journal: Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among breast cancer patients. (Pubmed Central) - Feb 6, 2017
Our study found racial disparities in women's use of oral NK1s for the prevention of CINV. These disparities may be partly explained by racial differences in women's ability to afford the medication.
- | Enrollment open: Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy (clinicaltrials.gov) - Jan 26, 2017
P3, N=116, Recruiting, Sponsor: Dr Atul Sharma
These disparities may be partly explained by racial differences in women's ability to afford the medication. Active, not recruiting --> Recruiting
- dexamethasone / Generic mfg., mirtazapine / Generic mfg.
Trial primary completion date: Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis (clinicaltrials.gov) - Jan 5, 2017
P3, N=212, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- || New P3 trial: Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy (clinicaltrials.gov) - Dec 1, 2016
P3, N=116, Active, not recruiting, Sponsor: Dr Atul Sharma
- |||| aprepitant oral / Generic mfg.
Trial primary completion date, CINV: Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) (clinicaltrials.gov) - Nov 23, 2016
P3, N=820, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Feb 2004 --> Dec 2004
- Januvia (sitagliptin) / Merck (MSD)
Trial primary completion date: Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=150, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Feb 2004 --> Dec 2004 Trial primary completion date: Jun 2017 --> Jun 2018
- || melphalan / Generic mfg., olanzapine / Generic mfg.
New P3 trial: Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (clinicaltrials.gov) - Oct 19, 2016
P3, N=370, Not yet recruiting, Sponsor: Rush University Medical Center
- |||| aprepitant oral / Generic mfg.
Trial completion: A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) (clinicaltrials.gov) - Oct 18, 2016
P2b, N=229, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed
- aprepitant oral / Generic mfg.
Enrollment change, Trial termination: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Sep 30, 2016
P2, N=4, Terminated, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed N=22 --> 4 | Recruiting --> Terminated; lack of eligible participants to enrol
- ||| aprepitant oral / Generic mfg.
Enrollment closed: A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) (clinicaltrials.gov) - Sep 21, 2016
P2b, N=260, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=22 --> 4 | Recruiting --> Terminated; lack of eligible participants to enrol Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial: Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 21, 2016
P3, N=298, Not yet recruiting, Sponsor: Sun Yat-sen University
- || ondansetron / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Jul 26, 2016
P2, N=136, Recruiting, Sponsor: Katy Peters
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- aprepitant oral / Generic mfg.
Enrollment open: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - May 27, 2016
P2, N=22, Recruiting, Sponsor: The Hospital for Sick Children
Trial primary completion date: Jun 2016 --> Jun 2017 Suspended --> Recruiting
- Sancuso (granisetron) / Cumberland
Trial suspension, Trial primary completion date: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=4, Suspended, Sponsor: Gynecologic Oncology Group
Suspended --> Recruiting Completed --> Suspended | Trial primary completion date: Mar 2013 --> May 2014
- || aprepitant oral / Generic mfg.
Trial completion: Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) (clinicaltrials.gov) - Feb 27, 2016
P3, N=50, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Suspended | Trial primary completion date: Mar 2013 --> May 2014 No longer recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P3, N=450, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-?) Release (clinicaltrials.gov) - Feb 24, 2016
P2, N=32, Completed, Sponsor: Mara Chambers
No longer recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 32 | Trial primary completion date: Dec 2014 --> Aug 2012
- ondansetron / Generic mfg.
Enrollment closed, Trial primary completion date: AVERT: Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy (clinicaltrials.gov) - Dec 29, 2015
P2, N=52, Active, not recruiting, Sponsor: University of Vermont
Active, not recruiting --> Completed | N=40 --> 32 | Trial primary completion date: Dec 2014 --> Aug 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Jul 2016
- ||| cisplatin / Generic mfg.
Trial initiation date, CINV: Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy (clinicaltrials.gov) - Nov 25, 2015
P2, N=80, Not yet recruiting, Sponsor: Zhejiang University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Jul 2016 Initiation date: May 2015 --> Nov 2015
- aprepitant oral / Generic mfg.
Trial suspension, Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Nov 19, 2015
P2, N=22, Suspended, Sponsor: The Hospital for Sick Children
Initiation date: May 2015 --> Nov 2015 Recruiting --> Suspended | Trial primary completion date: Sep 2015 --> Sep 2016
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
New trial, Combination therapy: Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=19, Terminated, Sponsor: University of Southern California
- |||| ondansetron / Generic mfg., cytarabine / Generic mfg.
Trial completion: Ondansetron Versus Aprepitant Plus Ondansetron for Emesis (clinicaltrials.gov) - Jun 25, 2015
P2, N=100, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended | Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed
- | aprepitant oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy (clinicaltrials.gov) - Jun 22, 2015
P2, N=41, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Recruiting --> Completed | N=82 --> 41 | Trial primary completion date: Mar 2014 --> Aug 2013
- Sancuso (granisetron) / Cumberland
Trial completion, Enrollment change, Trial primary completion date: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - May 28, 2015
P=N/A, N=4, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | N=82 --> 41 | Trial primary completion date: Mar 2014 --> Aug 2013 Suspended --> Completed | N=60 --> 4 | Trial primary completion date: Jan 2012 --> Mar 2013
- |||| cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Trial primary completion date, CINV: Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. (clinicaltrials.gov) - May 19, 2015
P4, N=212, Completed, Sponsor: Spanish Breast Cancer Research Group
Suspended --> Completed | N=60 --> 4 | Trial primary completion date: Jan 2012 --> Mar 2013 Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Mar 2013
- ||||| cisplatin / Generic mfg.
New P2 trial, CINV: Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy (clinicaltrials.gov) - May 15, 2015
P2, N=80, Not yet recruiting, Sponsor: Zhejiang University
- ||||| aprepitant oral / Generic mfg.
Trial initiation date: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) (clinicaltrials.gov) - Mar 11, 2015
P3, N=600, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Mar 2013 Initiation date: Jan 2002 --> Jul 2002
- ||||| aprepitant oral / Generic mfg.
Trial initiation date: Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED) (clinicaltrials.gov) - Mar 11, 2015
P3, N=800, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Jan 2002 --> Jul 2002 Initiation date: May 2002 --> Jan 2002
- ||||| aprepitant oral / Generic mfg.
Trial initiation date: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) (clinicaltrials.gov) - Mar 11, 2015
P3, N=540, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: May 2002 --> Jan 2002 Initiation date: Feb 2002 --> Nov 2001
- || ondansetron / Generic mfg.
Trial primary completion date: AVERT: Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy (clinicaltrials.gov) - Jan 26, 2015
P2, N=61, Recruiting, Sponsor: University of Vermont
Initiation date: Feb 2002 --> Nov 2001 Trial primary completion date: Jun 2014 --> Jun 2015
- |||||||||| dexamethasone / Generic mfg., mirtazapine / Generic mfg.
New P3 trial: Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis (clinicaltrials.gov) - Jan 13, 2015
P3, N=212, Recruiting, Sponsor: Fudan University
- || ondansetron / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Jan 9, 2015
P2, N=136, Recruiting, Sponsor: Katy Peters
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Dec 2014 --> Jun 2016
- aprepitant oral / Generic mfg.
Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Nov 25, 2014
P2, N=22, Recruiting, Sponsor: The Hospital for Sick Children
Trial primary completion date: Dec 2014 --> Jun 2016 Trial primary completion date: Mar 2015 --> Sep 2015
- |||| Decadron (dexamethasone) / Merck (MSD)
Trial completion, CINV: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (clinicaltrials.gov) - Oct 4, 2014
P4, N=494, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2015 --> Sep 2015 Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open: Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=150, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed Not yet recruiting --> Recruiting
- | New P2 trial: Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients (clinicaltrials.gov) - Aug 1, 2014
P2, N=134, Recruiting, Sponsor: Associazione Salentina Angela Serra
- mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-?) Release (clinicaltrials.gov) - Jun 26, 2014
P2, N=40, Active, not recruiting, Sponsor: Mara Chambers
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Dec 2014
- || aprepitant oral / Generic mfg.
Trial primary completion date: A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) (clinicaltrials.gov) - Jun 8, 2014
P2b, N=260, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Nov 2014 --> Oct 2016
- ||||| ondansetron intravenous / Generic mfg., aprepitant oral / Generic mfg.
Enrollment change: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) (clinicaltrials.gov) - May 19, 2014
P3, N=922, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Nov 2014 --> Oct 2016 N=720 --> 922
- aprepitant oral / Generic mfg.
Enrollment change: Differentiating the Effects of Substance P and Beta-endorphin (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=10, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
N=720 --> 922 N=20 --> 10
- aprepitant oral / Generic mfg.
Trial completion: Differentiating the Effects of Substance P and Beta-endorphin (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=10, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
N=20 --> 10 Recruiting --> Completed